SCHEMBL2380952

SCHEMBL2380952

COCNC(=O)c1cccc2cc(-c3cccc4cnccc34)ccc12

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 7/20 0.58
KDR P35968 3/20 0.46
CHEK1 O14757 1/20 0.46
NTSR1 P30989 1/20 0.44
SERPINE1 P05121 1/20 0.43
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLQ O75417 1/20 0.41
PREP P48147 2/20 0.41
DPP7 Q9UHL4 1/20 0.41
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
PIM1 P11309 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
AURKA O14965 1/20 0.40
MET P08581 1/20 0.40
TEK Q02763 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12245751 0.91 DGAT2 (0.57) DGAT2KDRCHEK1ALDH1A1SMN1; SMN2
SCHEMBL2379174 0.85 DGAT2 (0.55) DGAT2KDRCHEK1NTSR1SERPINE1
SCHEMBL14571338 0.81 DGAT2 (0.46) DGAT2KDRCHEK1NTSR1SERPINE1
SCHEMBL2380276 0.80 KDR (0.58) DGAT2KDRSERPINE1ALDH1A1TEK
SCHEMBL2380673 0.80 MCL1 (0.49) DGAT2KDRCHEK1NTSR1SERPINE1
SCHEMBL2380917 0.79 SERPINE1 (0.47) DGAT2KDRCHEK1NTSR1SERPINE1
SCHEMBL2381295 0.79 KDM4E (0.46) DGAT2KDRCHEK1NTSR1SERPINE1
SCHEMBL2380392 0.77 KDR (0.60) KDRSERPINE1ALDH1A1SMN1; SMN2AURKA
SCHEMBL2381046 0.77 KDR (0.49) DGAT2KDRNTSR1SERPINE1SMN1; SMN2
SCHEMBL2380290 0.77 KDR (0.49) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017601-B2 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2011-09-13 US disclosed
EP-1896461-A2 BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER Amgen Inc. (US) 2008-03-12 EP disclosed
US-20070054903-A1 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2007-03-08 US disclosed
WO-2007005668-A2 BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054903-A1 Bis-aryl kinase inhibitors and method HGF, MET, BLK DGAT2 3636/4885KDR 260/4885CHEK1 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.